<p>Digital therapeutics (DTx) are emerging as a transformative approach in healthcare, offering software-driven, evidence-based interventions for the prevention, management, and treatment of medical conditions such as chronic diseases, mental health disorders, and substance use disorders. Unlike general wellness applications or traditional digital health tools, DTx products are subject to rigorous clinical validation and regulatory scrutiny, ensuring their safety, efficacy, and integration into clinical practice. This manuscript explores the defining characteristics of digital therapeutics, differentiating them from other digital health technologies, and examines their role in patient-centric care. It further investigates global regulatory frameworks, including those in the United States, Europe, and Korea, highlighting the need for harmonized guidelines and structured approval pathways. The paper also discusses the importance of robust clinical trial design, validation methods, and post-market surveillance to support the adoption and reimbursement of DTx. Real-world examples such as EndeavorRx^®, reSET, DaylightRx and Somryst illustrate the growing potential of DTx to reshape medical treatment. As digital therapeutics continue to evolve, this review emphasizes the critical need for regulatory agility, evidence-based implementation, and collaborative efforts to fully realize their benefits within modern healthcare systems.</p>